Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last --
Change Today 0.00 / 0.00%
Volume 0.0
1530 On Other Exchanges
1530 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

3sbio inc (1530) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for 3SBIO INC (1530)

3sbio inc (1530) Related Bloomberg News

View More Bloomberg News

3sbio inc (1530) Related Businessweek News

No Related Businessweek News Found

3sbio inc (1530) Details

3SBio Inc., a biotechnology company, develops, manufactures, markets, and sells biopharmaceuticals in China. Its principal products include EPIAO, an injectable recombinant human erythropoietin for anemia associated with chronic kidney disease (CKD), and chemotherapy-induced anemia (CIA), as well as to reduce allogeneic blood transfusion in surgery patients; and TPIAO, a recombinant human thrombopoietin for chemotherapy-induced thrombocytopenia and immune thrombocytopenia. The company also offers IV Iron Sucrose, an iron sucrose injection product for iron deficiency anemia; SEPO, an injectable product for anemia associated with CKD, and CIA; and Sparin, an injectable low-molecular-weight heparin calcium product for prophylaxis and vein thrombosis, and to prevent clotting during hemodialysis. In addition, it provides Intefen, a recombinant human interferon alpha-2a product for the treatment of malignancies of the lymphatic or hematopoietic system, and viral infectious diseases; and Inleusin, a recombinant human interleukin 2 product for renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer, and tuberculosis; and Gan Xin, a metadoxine drug for alcoholic liver disease. Further, the company offers aseptic and terminally sterilized, and biological injectable products in various formats, such as pre-filled syringes, lyophilized vials, liquid vials, and ampoules, as well as helps customers in development process for the registration of new or generic drugs. Additionally, it distributes anti-cancer drugs, such as docetaxel, anastrozole, and azasetron. 3SBio Inc. is also developing various product candidates in the nephrology, oncology, auto-immune diseases, and other areas. The company sells its products through in-house sales and marketing team, distributors, and third-party promoters to hospitals and medical institutions. 3SBio Inc. was incorporated in 2006 and is headquartered in Shenyang, China. 3SBio Inc. is a subsidiary of Decade Sunshine Limited.

1,461 Employees
Last Reported Date: 09/24/15
Founded in 2006

3sbio inc (1530) Top Compensated Officers

Co Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: CNY912.0K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: CNY1.0M
Senior Vice President and Executive Director
Total Annual Compensation: CNY565.0K
Vice President and Executive Director
Total Annual Compensation: CNY40.0K
Compensation as of Fiscal Year 2014.

3sbio inc (1530) Key Developments

3SBio Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-13-2016 11:00 AM

3SBio Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-13-2016 11:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Jing Lou, Co Founder, Chairman, Chief Executive Officer, President and Chairman of Nomination Committee.

3SBio Inks Patent License Deal for ALT-P7

3SBio has entered into an exclusive licensing deal with Alteogen for the development, manufacturing and marketing of ALT-P7, a novel antibody-drug conjugate (ADC) targeting HER2 pathway for cancer in the territory of Mainland China, Hong Kong and Macau. ALT-P7 is a novel ADC with potential to treat refractory tumors.

3SBio Inc. Mulls Acquisitions

3SBio Inc. (SEHK:1530) is seeking acquistions. 3SBio is actively pursuing international expansion through acquisition, licensing and partnerships.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
1530:HK $9.00 HKD -0.54

1530 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Kirin Holdings Co Ltd ¥1,526 JPY -83.00
Roche Holding AG SFr.240.70 CHF -4.80
View Industry Companies

Industry Analysis


Industry Average

Valuation 1530 Industry Range
Price/Earnings 100.0x
Price/Sales 150.2x
Price/Book 50.0x
Price/Cash Flow 7.1x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact 3SBIO INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at